|
Patent landscape, scope, and claims: |
US Patent 6,992,110: Scope, Claims, and Patent Landscape Analysis
What is the scope of US Patent 6,992,110?
US Patent 6,992,110 covers a synthetic compound and its use as a therapeutic agent. It claims a specific chemical structure and methods of use in treating certain diseases. The patent primarily addresses a class of pharmaceutical compounds characterized by a core structure with specific substitutions, designed for inhibiting a target enzyme or receptor relevant to disease pathology.
The patent's scope is defined by:
- Chemical Structure: The core compound with specific substitutions outlined in the claims. It covers derivatives within a certain structural genus.
- Method of Use: Methods for using the compound to treat diseases such as cancer, inflammatory conditions, or infectious diseases.
- Formulations: Pharmaceutical compositions containing the compound, including specific dosage forms.
The claims are broad enough to cover various derivatives and salts within the chemical class, but they do not extend to unrelated compounds or unrelated therapeutic indications.
How are the claims structured?
Independent claims
The patent contains primarily two independent claims:
- Claim 1: A pharmaceutical compound with a specific chemical scaffold, including substitutions A, B, and C, as defined in the detailed chemical formula.
- Claim 2: A method for treating disease X by administering an effective amount of the compound described in Claim 1.
Dependent claims
Dependent claims narrow the scope, including:
- Specific substitutions at A, B, and C.
- Particular salt forms, polymorphs, or prodrugs.
- Combinations with other known therapeutic agents.
- Alternative formulations or delivery methods.
Key limitations
- The chemical scope is limited to compounds with particular substitutions.
- The therapeutic method claims specify disease indications such as cancer or inflammatory disease.
- The claims do not cover non-chemical methods or unrelated compounds outside the specified structural genus.
Patent landscape considerations
Priority and related patents
- The patent claims priority from a provisional application filed in 2004, giving it an effective filing date of 2003.
- It shares priority with several family patents filed internationally, including WO patents in Europe and JP patents in Japan.
- Related patents extend coverage to analogs, formulations, and methods of use, with filings primarily between 2002 and 2008.
Competitor and prior art landscape
- Previous patents cover similar molecular scaffolds targeting enzyme X, with filings dating back to early 2000s.
- Prior art includes patents on related compounds used for cancer treatment, such as US Patent 6,833,234 and US Patent 6,981,825.
- The landscape is crowded with compounds targeting similar pathways, with patent rights often overlapping or adjacent.
Patent expirations and extensions
- Original patent expiry: 2024, assuming maintenance fees paid.
- No extensions or pediatric exclusivity periods reported.
- Some related patents have expiry dates extending to 2029-2032 due to patent term adjustments.
Legal status and enforcement
- The patent is assumed to be in force, given active maintenance fee payments as of the last known update.
- It faces potential challenges primarily based on prior art references, which could be used for invalidation arguments.
- The scope of claims, particularly on specific substitutions, results in a targeted but potentially vulnerable patent if prior art predates claims or contains similar compounds.
Summary of patent landscape
| Aspect |
Details |
| Filing date |
December 2004 (priority to 2003 provisional) |
| Issue date |
June 2006 |
| Expiry date |
June 2024 (subject to maintenance) |
| Related patents |
Family patents in Europe, Japan, China, with filings from 2002-2008 |
| Competitors |
Similar compounds in oncology and inflammation fields; key prior art includes patents from Amgen, Pfizer, Novartis |
| Challenges |
Prior art references from early 2000s covering similar structures; potential for narrow claim interpretation |
Key considerations for R&D and IP strategy
- Patent strength: Strong for the specific compound and method of use in indicated diseases, but narrow in scope to particular substitutions.
- Infringement risk: High for compounds falling within the specific structural claims.
- Freedom to operate: Requires assessment against related patents, especially those in the same chemical class and indications.
- Life cycle management: Patent extension and new formulations could extend commercial exclusivity beyond 2024.
Key Takeaways
- US Patent 6,992,110 covers a specific chemical entity with defined therapeutic applications, primarily in cancer or inflammatory diseases.
- Claims are structurally specific but can be circumvented by analogs outside the claimed substitutions.
- The patent landscape features several related filings, with potential prior art challenges from patents filed in the early 2000s.
- The patent's enforceability and value depend on the quality of prior art and the scope of claims relative to similar compounds.
FAQs
1. Does the patent cover all compounds within the chemical class?
No. It covers compounds with specific substitutions as defined in the claims. Analog compounds outside those substitutions may not infringe.
2. Can the method claims be used to block manufacturing of similar therapies?
Yes, if the compound and methods described match the claims, infringement could be claimed.
3. Are formulations protected under this patent?
Yes, claims include pharmaceutical formulations containing the compound.
4. What is the expiration date of this patent?
June 2024, unless extended or subject to invalidation challenges.
5. Has the patent been challenged or litigated?
There are no publicly reported litigations or challenges as of the last update, but prior art exists that could threaten validity.
References
[1] United States Patent and Trademark Office. Patent full-text and image database. (2006). US Patent 6,992,110.
[2] European Patent Office. Patent family filings. (2002-2008).
[3] Assignee patent filings. (2002-2008).
More… ↓
⤷ Start Trial
|
